HiFiBiO Therapeutics

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease.

[HiFiBiO Therapeutics @hifibio]

HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with @NYSE Floor Talks to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies through AI/ML to enhance the probability of success in patients suffering from cancer and I&I diseases.

#HiFiBiOWay #Interview  #Immunotherapies #Innovation #NYSEFloorTalk

[NYSE 🏛 @NYSE]

Liang Schweizer, PhD, Founder & CEO of @hifibio, shares how the company stands out in biotech and uses AI to transform drug development on #NYSEFloorTalk with @JudyKShaw.

[HiFiBiO Therapeutics @hifibio]

We're so excited for #SITC2024! If you are also attending, don't forget to stop by our two posters showcasing our AI/ML clinical technology in two Phase 1 novel immuno-oncology programs: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).

Learn more about these two programs and their therapeutic potential, even in IO refractory tumors!

Can’t join in person? Our posters are now available on our website.
https://t.co/tX73DtY0pj

#cancer #aiandml #immunooncology #immunotherapy #innovation #DrugIntelligenceScience #TNFR2 #BTLA

[HiFiBiO Therapeutics @hifibio]

We are thrilled to share that the FDA has cleared our IND application for HFB200604, our first inflammation and immunology program!

HFB200604 is a best-in-class BTLA agonist monoclonal antibody developed using HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform. It is designed to restore immune tolerance in a host of autoimmune diseases by stimulating BTLA signaling in immune cells.

https://t.co/INUw138sd7

#autoimmune #inflammation #immunology #immunotherapy #innovation #BTLA #antibody #IND #agonist

[HiFiBiO Therapeutics @hifibio]

Come meet HiFiBiO's Timothy Miller at the upcoming #BIOEUROPE on November 4th to 6th in Stockholm, Sweden. Excited to connect and collaborate with fellow #biotech and #pharma leaders on partnership of our IO and I&I programs.

[HiFiBiO Therapeutics @hifibio]

HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #SITC2024 meeting, taking place Nov. 6-10 in Houston, Texas.

The company will present Drug Intelligence Science (DIS®) enabled translational insights from ongoing Phase 1 clinical trials for its first-in-class TNFR2 agonist HFB200301 (NCT05238883) and best-in-class BTLA antagonist HFB200603 (NCT05789069).

Come visit our posters to learn how DIS® is uncovering deep translational insights to enhance clinical success!
#cancer #aiandml #immunooncology #immunotherapy #innovation

[HiFiBiO Therapeutics @hifibio]

Exciting news! Join us at the #BiotechWeekBoston (BWB) Awards next Monday, September 23, where we’re honored to be among the finalists for the Start-up of the Year Award!

We’re also thrilled to announce that our CEO, Liang Schweizer, is named a Finalist for the prestigious Lifetime Achievement Award.

Under Liang’s visionary leadership, our passionate team has advanced a diverse portfolio of cutting-edge immunotherapies targeting cancers and autoimmune diseases, including three novel IO programs into Phase I. Furthermore, our single-cell and AI/ML powered Drug Intelligence Science (DIS®) translational platform represents a significant leap forward in precision medicine, allowing for more tailored therapies for individual patients and maximizing clinical success rates.

Click here to register for the event: https://t.co/NDFqdXQ7ek
#biotech #immunotherapy #innovation #DrugIntelligenceScience #leadership #BWB #StartupoftheYear #PrecisionMedicine #AI #CancerTherapies

[HiFiBiO Therapeutics @hifibio]

Our team enjoyed the exciting conversations around our two posters at #ESMO2024! We are thrilled to share the amazing Ph1 clinical trial results for HFB200301, a first-in-class TNFR2 agonist and HFB200603, a best-in-class BTLA antagonist.
The full posters are up on our website for viewing:
HFB200301: https://t.co/4mChg6Bacx
HFB200603: https://t.co/uMXkI9vXTx

[HiFiBiO Therapeutics @hifibio]

HiFiBiO Therapeutics will present interim Phase 1 clinical trial data for our first-in-class TNFR2 agonist (HFB200301) and best-in-class BTLA antagonist for solid tumors at the upcoming #ESMO2024.

Link to PR and abstract: https://t.co/3Ru9Sm0AN0

[HiFiBiO Therapeutics @hifibio]

HiFiBiO Therapeutics, a leading clinical stage immune modulation company, announced today its participation in the #ESMO2024 meeting, taking place Sep 13-17 in Barcelona, Spain. On Saturday, September 14, the company will present compelling Phase 1 trial data for two novel monoclonal antibodies: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069).

Come visit our posters to learn more about these two programs and their therapeutic potential in IO refractory tumors!

View the full press release here: https://t.co/zVaHrt28Rb
#cancer #aiandml #immunooncology #immunotherapy #innovation

[HiFiBiO Therapeutics @hifibio]

Thrilled to have CEO Liang Schweizer selected as a Finalist for the Lifetime Achievement Award and HiFiBiO Therapeutics recognized as a Finalist for the Start-up of the Year Award at #BiotechWeekBoston!

[HiFiBiO Therapeutics @hifibio]

Thrilled to have our CEO Liang Schweizer recognized among so many inspiring business leaders as a winner in the Entrepreneur Of The Year® New England program!
https://t.co/mjqR5wJXjg
#EOYUS #EOYNE

[HiFiBiO Therapeutics @hifibio]

June is #NationalCancerSurvivorMonth. Join HiFiBiO Therapeutics in honoring the over 18 million individuals in the U.S. living with a history of cancer and the unique challenges they continue to face (AACR https://t.co/RRizogwHDn).

Thanks to remarkable advances in cancer research, there have been significant improvements in cancer diagnostics and treatment, particularly in the field of cancer immunotherapies. However, substantial gaps remain. Many patients harbor cancers that either do not respond to current standard immunotherapies or experience relapse, limiting the potential benefits (https://t.co/ENcef7uqSi).

HiFiBiO Therapeutics is utilizing its DIS® translational platform to develop a pipeline of novel immune modulatory therapeutics aimed at overcoming these gaps. The company has advanced three cancer immunotherapies into Phase I trials, showing promising developments: the first-in-class anti-TNFR2 antibody HFB200301 (clinical trial NCT05238883), the next-generation OX40 agonist antibody HFB301001 (clinical trial NCT05229601), and the best-in-class BTLA antagonist antibody HFB200603 (clinical trial NCT05789069).

[HiFiBiO Therapeutics @hifibio]

There was amazing buzz around our two posters at #ASCO2024! Our team enjoyed the exciting discussions around the results of our two Ph1 clinical trials for best-in-class TNFR2 agonist HFB200301 and next-generation OX40 agonist HFB301001.
The e-posters are now up on our website for viewing.
HFB200301: https://t.co/TwQYps0Vgy
HFB301001: https://t.co/ND1nOPHiyp
HFB301001: https://t.co/ND1nOPHiyp

[HiFiBiO Therapeutics @hifibio]

Meet HiFiBiO's Timothy Miller at the upcoming #BIO2024 International Convention on June 3rd to 6th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders!

[HiFiBiO Therapeutics @hifibio]

Don't forget to stop by our two posters at #ASCO2024 as we release Phase 1 dose escalation data for our first-in-class TNFR2 agonist, HFB200301 and next-generation OX40 agonist HFB301001!

Link to press release for details: https://t.co/AUiVrEo0fh

[HiFiBiO Therapeutics @hifibio]

HiFiBiO Therapeutics will present Phase 1 clinical trial data for our first-in-class TNFR2 agonist (HFB200301) and next-generation OX40 agonist (HFB301001) for solid tumors at the upcoming #ASCO2024.

Link to press release and abstract: https://t.co/aeKq8mwRl1

[HiFiBiO Therapeutics @hifibio]

May is #AAPIHeritageMonth! Join HiFiBiO to celebrate all the Asian Americans, Native Hawaiians, and Pacific Islanders that have contributed greatly to our shared history.

[HiFiBiO Therapeutics @hifibio]

Meet HiFiBiO Therapeutics at this year’s Pharma Partnering Summit on May 14th – 15th in San Diego, CA. Looking forward to connect and collaborate with fellow biotech and pharma leaders!